Your browser doesn't support javascript.
loading
Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.
Berkowitz, Richard D; Steinfeld, Richard; Sah, Alexander P; Mack, Randall J; McCallum, Stewart W; Du, Wei; Black, Libby K; Freyer, Alex; Coyle, Erin.
Afiliación
  • Berkowitz RD; University Orthopedic and Joint Replacement Center, Tamarac, Florida, USA.
  • Steinfeld R; Orthopaedic Center of Vero Beach, Vero Beach, Florida, USA.
  • Sah AP; Institute for Joint Restoration & Research, Fremont, California, USA.
  • Mack RJ; Baudax Bio Inc., Malvern, Pennsylvania, USA.
  • McCallum SW; Baudax Bio Inc., Malvern, Pennsylvania, USA.
  • Du W; Clinical Statistics Consulting, Blue Bell, Pennsylvania, USA.
  • Black LK; Baudax Bio Inc., Malvern, Pennsylvania, USA.
  • Freyer A; Baudax Bio Inc., Malvern, Pennsylvania, USA.
  • Coyle E; Baudax Bio Inc., Malvern, Pennsylvania, USA.
Pain Med ; 22(6): 1261-1271, 2021 06 04.
Article en En | MEDLINE | ID: mdl-33502533
OBJECTIVE: To evaluate the effect of perioperative meloxicam IV 30 mg on opioid consumption in primary total knee arthroplasty (TKA). DESIGN: Multicenter, randomized, double-blind, placebo-controlled trial. SUBJECTS: In total, 181 adults undergoing elective primary TKA. METHODS: Subjects received meloxicam 30 mg or placebo via an IV bolus every 24 hours, the first dose administered prior to surgery as part of a multimodal pain management protocol. The primary efficacy parameter was total opioid use from end of surgery through 24 hours. RESULTS: Meloxicam IV was associated with less opioid use versus placebo during the 24 hours after surgery (18.9 ± 1.32 vs 27.7 ± 1.37 mg IV morphine equivalent dose; P < 0.001) and was superior to placebo on secondary endpoints, including summed pain intensity (first dose to 24 hours postdosing, first dose to first assisted ambulation, and first dose to discharge) and opioid use (48-72 hrs., 0-48 hrs., 0-72 hrs., hour 0 to end of treatment, and the first 24 hours after discharge). Adverse events (AEs) were reported for 69.9% and 92.0% of the meloxicam IV and placebo groups, respectively; the most common AEs were nausea (40% vs. 59%), vomiting (16% vs 22%), hypotension (14% vs 15%), pruritus (15% vs 11%), and constipation (11% vs 13%). CONCLUSIONS: Perioperative meloxicam IV 30 mg as part of a multimodal analgesic regimen for elective primary TKA reduced opioid consumption in the 24-hour period after surgery versus placebo and was associated with a lower incidence of AEs typically associated with opioid use.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artroplastia de Reemplazo de Rodilla Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Pain Med Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artroplastia de Reemplazo de Rodilla Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: Pain Med Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido